Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04695171
Other study ID # TRX-2019-02
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 14, 2021
Est. completion date January 2028

Study information

Verified date September 2023
Source Foregut Research Foundation
Contact Rachel Heidrick, BSN
Phone 303-788-7700
Email rachel@iersurgery.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The cohort registry is both retrospective and prospective, multicenter surveillance of subjects who underwent a prior hiatal hernia repair and Magnetic Sphincter Augmentation or fundoplication construction more than 2 years prior to initial study visit.


Description:

The cohort registry is both retrospective and prospective, multicenter surveillance of subjects who underwent a prior hiatal hernia repair and anti-reflux surgery with either Magnetic Sphincter Augmentation (MSA) using LINX placement or fundoplication construction more than 2 years prior to initial study visit. Subjects will be enrolled by invitation only by participating investigators. Enrollment will consist of 300 LINX MSA patients and 150 fundoplication patients with a total of 450 from 4 sites within the United States. Data will be collected for up to 6 years.The primary objective of this study is to determine the long-term incidence of hiatal hernia recurrence in patients who undergo hiatal hernia repair of a large (>3 cm) hernia with LINX® device placement, and to compare this with hiatal hernia recurrence rates in patients who underwent hiatal hernia repair with fundoplication.


Recruitment information / eligibility

Status Recruiting
Enrollment 450
Est. completion date January 2028
Est. primary completion date January 2027
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: 1. Subject must be at least 21 years of age and at least the minimum Age of Majority according to applicable state law. 2. Underwent primary index procedure of laparoscopic repair of a hiatal hernia larger than 3 cm with placement of a LINX® device or construction of a fundoplication for reflux control more than 2 years prior to his/her enrollment or has completed 1 or 2 of the barium swallows and GERD-HRQLs within study time points with or without hiatal hernia recurrence. 3. Subject is willing and able to cooperate with follow-up examinations. 4. Subject has been informed of the study procedures and treatment and has signed an informed consent. Exclusion Criteria: 1. The surgical procedure was completed as an emergency procedure 2. Currently being treated with another investigational drug or investigational device 3. Suspected or confirmed esophageal or gastric cancer 4. Subject has Barrett's esophagus >3cm 5. Cannot understand trial requirements or is unable to comply with follow-up schedule 6. Pregnant or plans to become pregnant during the course of the study 7. Medical illness (i.e. congestive heart failure) that may cause the subject to be non-compliant with or able to meet the protocol requirements or is associated with limited life expectancy (i.e. less than 3 years) 8. Diagnosed psychiatric disorder (e.g. bipolar, schizophrenia, etc.), subjects that exhibit depression that are on appropriate medication(s) are allowable.

Study Design


Intervention

Device:
LINX Reflux Management System
The LINX Reflux Management System consists of a series of titanium beads each with a magnetic core connected with independent titanium wires to form an annular shape when implanted. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak lower esophageal sphincter (LES) closed. During swallowing, the magnetic beads slide away from each other on the independent titanium wire "links" to allow esophageal distention as the bolus passes by.
Procedure:
Fundoplication
A surgical procedure where the fundus of the stomach is wrapped around and sutured to the distal esophagus to restore the function of the lower esophageal sphincter in limiting stomach contents from refluxing into the esophagus.

Locations

Country Name City State
United States University of Texas Austin Texas
United States South Florida Reflux Center Coral Springs Florida
United States East Carolina University Greenville North Carolina
United States Institute of Esophageal and Reflux Surgery Lone Tree Colorado
United States Keck Medical Center of USC Los Angeles California
United States Esophageal Institute Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Foregut Research Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Hiatal Hernia Recurrence The primary objective of this study is to determine the long-term incidence of hiatal hernia recurrence in patients who undergo primary hiatal hernia repair of a large (>3 cm) hernia with LINX® device placement, and to compare this with hiatal hernia recurrence rates in patients who undergo hiatal hernia repair with fundoplication. Up to 5 years post index procedure
Secondary Incidence of Repeat Surgical Intervention A secondary objectives are to determine the incidence of repeat surgical intervention with recurrent hernias in patients who received a LINX verses fundoplication. 5 years
Secondary Understanding Patient Reported Symptom Control A secondary objective is to understand patient-reported symptom control including PPI use, occurrence rate of gas and bloating, and ability to belch and vomit as measured by comparison of pre- and post-operative satisfaction and ROARS Questionnaire (GERD-Health related quality of life [HRQL]) surveys during multiple follow-up time points. 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT06025773 - A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121 Phase 1
Recruiting NCT06280664 - Efficacy Of Hiatal Closure For GERD
Recruiting NCT05359965 - Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF N/A
Completed NCT04202692 - Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment N/A
Active, not recruiting NCT03646045 - Transpyloric Feeding for Prevention of Micro-aspiration
Recruiting NCT06430047 - Efficacy and Safety of EsoDuo® Phase 4
Completed NCT04268719 - Near Focus NBI-Driven Artificial Intelligence for the Diagnosis of Gastro-Oesophageal Reflux Disease
Active, not recruiting NCT04614974 - Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia Phase 1/Phase 2
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Recruiting NCT03868267 - Japanese Upper GI Symptoms Compared With Iranian and Canadian Patients Presenting
Terminated NCT04028466 - Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features Phase 4
Active, not recruiting NCT05371717 - Domiciliary Management of Dental Erosion in Patients With GERD With Biomimetic Hydroxyapatite N/A
Recruiting NCT05066594 - Observational Registry of Transoral Incisionless Fundoplication (TIF) for Gastroesophageal Reflux Disease (GERD)
Completed NCT03476265 - Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motility N/A
Completed NCT03143608 - GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery N/A
Completed NCT04436159 - Partial Versus Total Fundoplication in the Surgical Repair of Para-esophageal Hernia. N/A
Completed NCT03258528 - Effect of Right Lateral Position on Ventilated Preterm Neonates N/A
Active, not recruiting NCT04500288 - The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot Study N/A
Completed NCT04262648 - Randomized Placebo-controlled Study of L. Reuteri NCIMB 30351 in GI Functional Disorders and Food Allergy in Newborns N/A
Recruiting NCT04846010 - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 Phase 1/Phase 2